The evaluation of changes in albuminuria was limited by the small number of patients with available UACR measurements and few patients underwent longitudinal, repeated assessments
1 In the REIMAGINE 2 trial, the most commonly reported AEs were GI-related, occurring in 405/603 (67.2%) participants in the CagriSema 2.4 mg/2.4 mg group, 326/605 (53.9%) participants in the semaglutide 2.4 mg group, 60/152 (39.5%) participants in the cagrilintide 2.4 mg group, 329/594 (55.4%) participants in the CagriSema 1 mg/1 mg group, 288/608 (47.4%) participants in the semaglutide 1 mg group, and 42/149 (28.2%) participants in the placebo group
Unlike typical GLP-1 stomach issues, pancreatitis pain is severe, travels to your back, and often comes with vomiting that brings no relief
How Slowed Gastric Emptying Affects Oral Medications This is the mechanism that matters most
A subscription helps protect your progress by ensuring uninterrupted treatment as part of your personalised CheqUp programme
Long-term considerations Remember that both medications work best when combined with healthy eating habits and regular physical activity